Unió Europea - anglès - EMA (European Medicines Agency)

teva b.v.  - lamivudine - hiv infections - antivirals for systemic use - lamivudine teva pharma b.v. is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (hiv)-infected adults and children.

Unió Europea - anglès - EMA (European Medicines Agency)

teva pharma b.v.  - lamivudine, zidovudine - hiv infections - antivirals for systemic use - lamivudine/zidovudine teva is indicated in antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (hiv) infection.

Unió Europea - anglès - EMA (European Medicines Agency)

ratiopharm gmbh - leflunomide - arthritis, rheumatoid - immunosuppressants - leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (dmard);active psoriatic arthritis.recent or concurrent treatment with hepatotoxic or haematotoxic dmards (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.moreover, switching from leflunomide to another dmard without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.

Unió Europea - anglès - EMA (European Medicines Agency)

actavis group ptc ehf - levetiracetam - epilepsy - antiepileptics, - levetiracetam actavis is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.levetiracetam actavis is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults, children and infants from one month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Unió Europea - anglès - EMA (European Medicines Agency)

ratiopharm gmbh - levetiracetam - epilepsy - antiepileptics, - levetiracetam ratiopharm is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.levetiracetam ratiopharm is indicated as adjunctive therapy:in the treatment of partial onset seizures with or without secondary generalisation in adults, children and infants from 1 month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Unió Europea - anglès - EMA (European Medicines Agency)

teva b.v. - levetiracetam - epilepsy - nervous system - levetiracetam teva is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.levetiracetam teva is indicated as adjunctive therapy:in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

Unió Europea - anglès - EMA (European Medicines Agency)

ratiopharm gmbh - memantine hydrochloride - alzheimer disease - psychoanaleptics, - treatment of patients with moderate to severe alzheimer’s disease

Unió Europea - anglès - EMA (European Medicines Agency)

teva pharma b.v. - mycophenolate mofetil - graft rejection - immunosuppressants - mycophenolate mofetil teva is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.

Unió Europea - anglès - EMA (European Medicines Agency)

teva b.v. - mycophenolate mofetil - graft rejection - immunosuppressants - myfenax is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants.

Unió Europea - anglès - EMA (European Medicines Agency)

actavis group ptc ehf. - memantine - alzheimer disease - psychoanaleptics, , other anti-dementia drugs - treatment of patients with moderate to severe alzheimer’s disease.